Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol VTCN1 contributors: - updated : 20-08-2007
HGNC name V-set domain containing T cell activation inhibitor 1
HGNC id 28873
Location 1p13.1      Physical location : 117.686.209 - 117.753.549
Synonym name
  • T cell costimulatory molecule B7x
  • immune costimulatory protein B7-H4
    • Synonym symbol(s) B7X; B7H4, B7S1, B7-H4, B7h.5, VCTN1, PRO1291, FLJ22418
    DNA
    TYPE functioning gene
    STRUCTURE 67.00 kb     7 Exon(s)
    MAPPING cloned Y linked N status provisional
    RNA
    TRANSCRIPTS type messenger
    EXPRESSION
    Type widely
    constitutive of
       expressed in (based on citations)
    organ(s)
    SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
    Digestivemouth   highly
    Reproductivefemale systemovary  highly
    Respiratoryrespiratory tracttrachea  highly
    cell lineage
    cell lines
    fluid/secretion
    at STAGE
    PROTEIN
    PHYSICAL PROPERTIES
    STRUCTURE
    motifs/domains
    HOMOLOGY
    Homologene
    FAMILY B7 family
    CATEGORY immunity/defense , antigen
    SUBCELLULAR LOCALIZATION
    basic FUNCTION
  • functioning as a negative regulator of T cell responses
  • negatively regulates T cell immunity by the inhibition of T cell proliferation, cytokine production, and cell cycle progression
  • playing a potential role in the evasion of tumor immunity
  • potential activator that promotes tubular lesion
    • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein expressed on the surface of antigen-presenting cells and interact with ligands (CD28 on T lymphocytes)
    cell & other
    REGULATION
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in serous ovarian cancers and breast cancers with relatively little or no expression in normal tissues
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target therapeutic antibody strategy aimed at VTCN1 could offer an exciting opportunity to inhibit the growth and progression of human ovarian and breast cancers
    ANIMAL & CELL MODELS